What is the price target for CR stock?
18 analysts have analysed CR and the average price target is 223.29 USD. This implies a price increase of 29.13% is expected in the next year compared to the current price of 172.92.
NYSE:CR • US2244081046
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CRANE CO (CR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-29 | DA Davidson | Maintains | Buy -> Buy |
| 2026-01-23 | Stifel | Maintains | Hold -> Hold |
| 2025-12-16 | Stifel | Maintains | Hold -> Hold |
| 2025-10-30 | DA Davidson | Maintains | Buy -> Buy |
| 2025-10-29 | Stifel | Maintains | Hold -> Hold |
| 2025-10-28 | DA Davidson | Maintains | Buy -> Buy |
| 2025-08-21 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-30 | DA Davidson | Maintains | Buy -> Buy |
| 2025-07-30 | UBS | Maintains | Buy -> Buy |
| 2025-07-30 | Stifel | Maintains | Hold -> Hold |
| 2025-07-21 | Stifel | Maintains | Hold -> Hold |
| 2025-06-10 | DA Davidson | Maintains | Buy -> Buy |
| 2025-06-10 | UBS | Maintains | Buy -> Buy |
| 2025-06-10 | Deutsche Bank | Maintains | Buy -> Buy |
| 2025-04-30 | Stifel | Maintains | Hold -> Hold |
| 2025-04-29 | UBS | Upgrade | Neutral -> Buy |
| 2025-04-14 | Stifel | Maintains | Hold -> Hold |
| 2025-03-11 | DA Davidson | Maintains | Buy -> Buy |
| 2025-01-30 | DA Davidson | Maintains | Buy -> Buy |
| 2025-01-24 | Stifel | Maintains | Hold -> Hold |
| 2025-01-03 | UBS | Maintains | Neutral -> Neutral |
| 2024-11-18 | Stifel | Downgrade | Buy -> Hold |
| 2024-10-16 | Stifel | Maintains | Buy -> Buy |
| 2024-10-03 | Deutsche Bank | Maintains | Buy -> Buy |
| 2024-08-01 | Deutsche Bank | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.862B 4.81% | 2.131B 14.45% | 2.305B 8.16% | 2.95B 27.98% | 3.124B 5.90% | 3.285B 5.15% | 3.515B 7.00% | 3.686B 4.86% | |
| EBITDA YoY % growth | 285.8M 41.91% | 406.8M 42.34% | 474.4M 16.62% | 627.62M 32.30% | 693.65M 10.52% | 767.92M 10.71% | 834.23M 8.64% | 875.76M 4.98% | |
| EBIT YoY % growth | 250.4M 49.31% | 355.8M 42.09% | 424.2M 19.22% | 578.34M 36.34% | 645.9M 11.68% | 704.05M 9.00% | 774.11M 9.95% | 806.28M 4.16% | |
| Operating Margin | 13.45% | 16.69% | 18.40% | 19.60% | 20.68% | 21.43% | 22.02% | 21.87% | |
| EPS YoY % growth | 4.28 -44.42% | 5.16 20.56% | 6.04 17.05% | 6.88 13.90% | 7.78 13.08% | 8.96 15.19% | 9.94 10.92% | 10.95 10.16% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.49 7.23% | 1.63 9.92% | 1.87 13.84% | 1.90 23.90% | 1.76 17.92% | 1.90 16.50% | 2.06 10.42% | 2.21 16.66% | 2.07 17.78% | 2.25 18.48% | 2.35 13.91% | 2.61 17.84% |
| Revenue Q2Q % growth | 692.63M 24.22% | 718.96M 24.56% | 766.32M 30.06% | 773.63M 33.15% | 729.65M 5.34% | 767.31M 6.72% | 809.03M 5.57% | 830.76M 7.38% | 778.17M 6.65% | 816.28M 6.38% | 846.56M 4.64% | 891.77M 7.34% |
| EBITDA Q2Q % growth | 138.55M 21.96% | 149.66M 16.47% | 168.73M 8.02% | 171.16M 12.61% | 165.62M 19.54% | 177.78M 18.79% | 184.78M 9.51% | 197.35M 15.30% | 184.47M 11.38% | 197.76M 11.24% | 205.38M 11.15% | 219.08M 11.01% |
| EBIT Q2Q % growth | 127.8M 26.41% | 138.27M 34.37% | 156.59M 32.26% | 159.14M 56.33% | 148.78M 16.42% | 159.24M 15.17% | 171.19M 9.32% | 179.17M 12.59% | 169.54M 13.95% | 182.83M 14.81% | 190.45M 11.25% | 204.15M 13.94% |
All data in USD
18 analysts have analysed CR and the average price target is 223.29 USD. This implies a price increase of 29.13% is expected in the next year compared to the current price of 172.92.
CRANE CO (CR) will report earnings on 2026-04-27, after the market close.
The consensus EPS estimate for the next earnings of CRANE CO (CR) is 1.49 USD and the consensus revenue estimate is 692.63M USD.
The consensus rating for CRANE CO (CR) is 83.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.